Loading...

PerkinElmer

DB:PKN
Snowflake Description

Acceptable track record with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PKN
DB
$10B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The last earnings update was 19 days ago. More info.


Add to Portfolio Compare Print
PKN Share Price and Events
7 Day Returns
0.8%
DB:PKN
-0.3%
Europe Life Sciences
-2.3%
DE Market
1 Year Returns
20.9%
DB:PKN
16.8%
Europe Life Sciences
-11.5%
DE Market
PKN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
PerkinElmer (PKN) 0.8% -7% -3.7% 20.9% 59.5% 141%
Europe Life Sciences -0.3% 4.1% 12.2% 16.8% 74.7% 195.7%
DE Market -2.3% -4.9% 0.8% -11.5% 5.7% 6.6%
1 Year Return vs Industry and Market
  • PKN outperformed the Life Sciences industry which returned 16.8% over the past year.
  • PKN outperformed the Market in Germany which returned -11.5% over the past year.
Price Volatility
PKN
Industry
5yr Volatility vs Market

PKN Value

 Is PerkinElmer undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of PerkinElmer to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for PerkinElmer.

DB:PKN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 10 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.9%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:PKN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Life Sciences Unlevered Beta Simply Wall St/ S&P Global 1.02
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.016 (1 + (1- 21%) (21.59%))
1.127
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.13
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.127 * 5.96%)
6.94%

Discounted Cash Flow Calculation for DB:PKN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for PerkinElmer is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:PKN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.94%)
2019 410.07 Analyst x3 383.44
2020 472.61 Analyst x3 413.24
2021 551.54 Analyst x2 450.94
2022 611.46 Est @ 10.86% 467.48
2023 658.38 Est @ 7.67% 470.67
2024 694.20 Est @ 5.44% 464.06
2025 721.11 Est @ 3.88% 450.75
2026 741.17 Est @ 2.78% 433.22
2027 756.11 Est @ 2.02% 413.26
2028 767.30 Est @ 1.48% 392.14
Present value of next 10 years cash flows $4,339.20
DB:PKN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $767.30 × (1 + 0.23%) ÷ (6.94% – 0.23%)
$11,452.93
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $11,452.93 ÷ (1 + 6.94%)10
$5,853.28
DB:PKN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $4,339.20 + $5,853.28
$10,192.48
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $10,192.48 / 110.92
$91.89
DB:PKN Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:PKN represents 0.90979x of NYSE:PKI
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.90979x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 91.89 x 0.90979
€83.60
Value per share (EUR) From above. €83.60
Current discount Discount to share price of €78.57
= -1 x (€78.57 - €83.60) / €83.60
6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price PerkinElmer is available for.
Intrinsic value
6%
Share price is €78.57 vs Future cash flow value of €83.6
Current Discount Checks
For PerkinElmer to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • PerkinElmer's share price is below the future cash flow value, but not at a moderate discount (< 20%).
  • PerkinElmer's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for PerkinElmer's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are PerkinElmer's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:PKN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $2.23
NYSE:PKI Share Price ** NYSE (2019-05-24) in USD $86.36
Europe Life Sciences Industry PE Ratio Median Figure of 17 Publicly-Listed Life Sciences Companies 39.53x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 20.2x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of PerkinElmer.

DB:PKN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NYSE:PKI Share Price ÷ EPS (both in USD)

= 86.36 ÷ 2.23

38.69x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PerkinElmer is good value based on earnings compared to the Europe Life Sciences industry average.
  • PerkinElmer is overvalued based on earnings compared to the Germany market.
Price based on expected Growth
Does PerkinElmer's expected growth come at a high price?
Raw Data
DB:PKN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 38.69x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts
19.8%per year
Europe Life Sciences Industry PEG Ratio Median Figure of 13 Publicly-Listed Life Sciences Companies 3.02x
Germany Market PEG Ratio Median Figure of 271 Publicly-Listed Companies 1.5x

*Line of best fit is calculated by linear regression .

DB:PKN PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 38.69x ÷ 19.8%

1.95x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PerkinElmer is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on PerkinElmer's assets?
Raw Data
DB:PKN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $23.79
NYSE:PKI Share Price * NYSE (2019-05-24) in USD $86.36
Europe Life Sciences Industry PB Ratio Median Figure of 36 Publicly-Listed Life Sciences Companies 2.69x
Germany Market PB Ratio Median Figure of 577 Publicly-Listed Companies 1.77x
DB:PKN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NYSE:PKI Share Price ÷ Book Value per Share (both in USD)

= 86.36 ÷ 23.79

3.63x

* Primary Listing of PerkinElmer.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PerkinElmer is overvalued based on assets compared to the Europe Life Sciences industry average.
X
Value checks
We assess PerkinElmer's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Life Sciences industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Life Sciences industry average (and greater than 0)? (1 check)
  5. PerkinElmer has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PKN Future Performance

 How is PerkinElmer expected to perform in the next 1 to 3 years based on estimates from 10 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
19.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is PerkinElmer expected to grow at an attractive rate?
  • PerkinElmer's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • PerkinElmer's earnings growth is expected to exceed the Germany market average.
  • PerkinElmer's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:PKN Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:PKN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 10 Analysts 19.8%
DB:PKN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 10 Analysts 6.2%
Europe Life Sciences Industry Earnings Growth Rate Market Cap Weighted Average 13.9%
Europe Life Sciences Industry Revenue Growth Rate Market Cap Weighted Average 7.6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 13.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:PKN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:PKN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 3,736 1
2022-12-31 3,523 1
2021-12-31 3,319 646 472 4
2020-12-31 3,135 560 419 8
2019-12-31 2,925 492 342 8
DB:PKN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 2,783 320 247
2018-12-30 2,778 311 237
2018-09-30 2,663 280 128
2018-07-01 2,543 245 149
2018-04-01 2,387 220 147
2017-12-31 2,257 288 157
2017-10-01 2,182 309 258
2017-07-02 2,142 324 215
2017-04-02 2,132 372 210
2017-01-01 2,116 351 216
2016-10-02 1,999 327 198
2016-07-03 2,048 314 199
2016-04-03 2,076 281 190

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • PerkinElmer's earnings are expected to grow by 19.8% yearly, however this is not considered high growth (20% yearly).
  • PerkinElmer's revenue is expected to grow by 6.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:PKN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below

All data from PerkinElmer Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PKN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 4.14 4.41 3.84 3.00
2020-12-31 3.72 4.03 3.24 5.00
2019-12-31 3.06 3.40 2.77 5.00
DB:PKN Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 2.23
2018-12-30 2.15
2018-09-30 1.16
2018-07-01 1.35
2018-04-01 1.33
2017-12-31 1.43
2017-10-01 2.35
2017-07-02 1.96
2017-04-02 1.92
2017-01-01 1.97
2016-10-02 1.80
2016-07-03 1.79
2016-04-03 1.70

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • PerkinElmer is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess PerkinElmer's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
PerkinElmer has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PKN Past Performance

  How has PerkinElmer performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare PerkinElmer's growth in the last year to its industry (Life Sciences).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • PerkinElmer's year on year earnings growth rate has been positive over the past 5 years.
  • PerkinElmer's 1-year earnings growth exceeds its 5-year average (68% vs 2.4%)
  • PerkinElmer's earnings growth has exceeded the Europe Life Sciences industry average in the past year (68% vs 14.8%).
Earnings and Revenue History
PerkinElmer's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from PerkinElmer Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PKN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 2,782.76 246.89 789.52 195.99
2018-12-30 2,778.00 237.48 787.47 194.00
2018-09-30 2,663.28 127.71 761.44 179.76
2018-07-01 2,543.24 148.81 718.54 165.80
2018-04-01 2,386.84 146.86 667.07 152.16
2017-12-31 2,256.98 156.89 620.46 139.46
2017-10-01 2,182.12 257.62 586.67 134.66
2017-07-02 2,142.34 214.99 580.20 129.29
2017-04-02 2,131.62 210.02 584.28 127.59
2017-01-01 2,115.52 215.71 584.59 124.18
2016-10-02 1,999.33 198.00 573.66 107.99
2016-07-03 2,048.27 198.98 582.77 109.58
2016-04-03 2,075.94 190.22 582.84 110.39
2016-01-03 2,104.82 188.79 585.70 112.54
2015-10-04 2,262.63 175.52 661.39 126.86
2015-06-28 2,241.25 163.52 656.83 126.21
2015-03-29 2,233.51 166.53 655.59 123.88
2014-12-28 2,069.88 130.14 647.87 108.06
2014-09-28 2,220.70 203.31 576.24 122.96
2014-06-29 2,200.75 201.17 576.84 123.73
2014-03-30 2,185.25 176.44 579.27 127.78
2013-12-29 2,157.59 174.27 580.85 132.40
2013-09-29 2,138.64 84.62 622.26 133.15
2013-06-30 2,126.14 72.85 626.67 134.35
2013-03-31 2,107.26 79.14 627.90 134.01
2012-12-30 2,105.19 71.29 627.92 131.84
2012-09-30 2,081.61 1.41 668.18 130.60
2012-07-01 2,024.95 0.42 652.18 128.30

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • PerkinElmer has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • PerkinElmer used its assets less efficiently than the Europe Life Sciences industry average last year based on Return on Assets.
  • PerkinElmer's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess PerkinElmer's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Life Sciences industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
PerkinElmer has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PKN Health

 How is PerkinElmer's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up PerkinElmer's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • PerkinElmer is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • PerkinElmer's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of PerkinElmer's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from PerkinElmer Company Filings, last reported 1 month ago.

DB:PKN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 2,638.47 2,068.05 134.25
2018-12-30 2,584.96 1,891.48 163.11
2018-09-30 2,572.47 1,902.57 149.51
2018-07-01 2,517.18 2,001.27 163.39
2018-04-01 2,555.25 2,077.45 180.80
2017-12-31 2,503.19 2,006.11 202.13
2017-10-01 2,536.03 1,110.56 709.49
2017-07-02 2,438.64 1,091.62 616.31
2017-04-02 2,208.99 1,054.86 288.33
2017-01-01 2,153.57 1,046.43 359.27
2016-10-02 2,135.42 1,133.09 311.66
2016-07-03 2,088.20 1,058.08 248.08
2016-04-03 2,049.48 1,120.97 210.73
2016-01-03 2,110.44 1,012.89 237.93
2015-10-04 2,054.32 1,028.38 195.07
2015-06-28 2,120.90 988.43 192.17
2015-03-29 2,059.89 1,015.75 168.92
2014-12-28 2,042.10 1,046.47 174.82
2014-09-28 2,062.75 859.74 203.68
2014-06-29 2,055.99 895.33 205.26
2014-03-30 2,029.44 929.52 224.11
2013-12-29 1,994.49 934.73 173.24
2013-09-29 1,919.57 935.91 132.30
2013-06-30 1,859.85 1,004.07 112.47
2013-03-31 1,834.42 1,026.65 125.87
2012-12-30 1,939.81 940.60 171.44
2012-09-30 1,942.44 932.33 170.83
2012-07-01 1,885.33 911.04 171.40
  • PerkinElmer's level of debt (78.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (45.8% vs 78.4% today).
  • Debt is not well covered by operating cash flow (15.5%, less than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 6x coverage).
X
Financial health checks
We assess PerkinElmer's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. PerkinElmer has a total score of 2/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PKN Dividends

 What is PerkinElmer's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0.32%
Current annual income from PerkinElmer dividends. Estimated to be 0.32% next year.
If you bought €2,000 of PerkinElmer shares you are expected to receive €6 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • PerkinElmer's pays a lower dividend yield than the bottom 25% of dividend payers in Germany (1.45%).
  • PerkinElmer's dividend is below the markets top 25% of dividend payers in Germany (3.89%).
Upcoming dividend payment

Purchase PerkinElmer before the 'Buy Limit' to receive their next dividend payment.

Dividends are usually paid every 3 or 6 months, you can time your share purchase to take advantage of upcoming dividend payments.
Dividend payment calendar
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:PKN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 10 Analyst Estimates (S&P Global) See Below
Europe Life Sciences Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 0.8%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:PKN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.28 6.00
2020-12-31 0.28 8.00
2019-12-31 0.28 8.00
DB:PKN Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-04-25 0.280 0.308
2019-01-24 0.280 0.297
2018-10-24 0.280 0.341
2018-07-23 0.280 0.316
2018-04-26 0.280 0.372
2018-01-26 0.280 0.368
2017-10-27 0.280 0.379
2017-07-24 0.280 0.413
2017-04-28 0.280 0.431
2017-01-27 0.280 0.500
2016-10-26 0.280 0.539
2016-07-27 0.280 0.516
2016-04-25 0.280 0.523
2016-01-28 0.280 0.583
2015-10-29 0.280 0.547
2015-07-23 0.280 0.575
2015-04-27 0.280 0.535
2015-01-23 0.280 0.581
2014-10-23 0.280 0.643
2014-07-24 0.280 0.636
2014-04-22 0.280 0.617
2014-01-24 0.280 0.630
2013-10-24 0.280 0.710
2013-07-26 0.280 0.758
2013-06-13 0.280 0.839
2013-01-25 0.280 0.838
2012-10-24 0.280 0.879
2012-07-27 0.280 0.988
2012-06-27 0.280 1.122
2012-01-30 0.280 1.057
2011-12-16 0.280 1.314
2011-07-25 0.280 1.387
2011-06-14 0.280 1.057
2011-01-24 0.280 1.044
2010-10-27 0.280 1.132
2010-07-30 0.280 1.263
2010-06-03 0.280 1.354
2010-01-25 0.280 1.227
2009-10-21 0.280 1.406
2009-06-12 0.280 1.542

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • PerkinElmer is not paying a notable dividend for Germany, therefore no need to check if the payments are stable.
  • PerkinElmer is not paying a notable dividend for Germany, therefore no need to check if the payments are increasing.
Current Payout to shareholders
What portion of PerkinElmer's earnings are paid to the shareholders as a dividend.
  • No need to calculate the sustainability of PerkinElmer's dividends as it is not paying a notable one for Germany.
Future Payout to shareholders
  • No need to calculate the sustainability of PerkinElmer's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess PerkinElmer's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can PerkinElmer afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. PerkinElmer has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PKN Management

 What is the CEO of PerkinElmer's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Rob Friel
COMPENSATION $13,961,376
AGE 62
TENURE AS CEO 11.3 years
CEO Bio

Mr. Robert F. Friel, also known as Rob, has been the Chairman of PerkinElmer Inc. since April 29, 2009 and also its Executive Director since January 1, 2006. He has been the Chairman of PerkinElmer LAS (Germany) GmbH since April 2009 and also has been its Chief Executive Officer and President since February 2008 and August 2007 respectively. Mr. Friel has been the Chief Executive Officer of PerkinElmer, Inc. since February 2008 and August 1, 2007 respectively. He served as President of PerkinElmer, Inc. since August 1, 2007 to January 1, 2019. He served as the Chief Operating Officer of PerkinElmer from August 1, 2007 to February 2008, Chief Financial Officer from February 1999 to January 1, 2006, Executive Vice President from October 2004 to January 1, 2006 and Senior Vice President from February 1999 to January 2006. From 1997 to 1999, he served as the Corporate Vice President and Treasurer of AlliedSignal Inc. He served as the President of Life and Analytical Sciences, a unit of PerkinElmer from January 2006 to August 2007. He served as a Vice President of Finance and Administration of AlliedSgnal Engines from 1992 to 1996. He joined PerkinElmer in 1999. He served for Nineteen years for Allied Signal Inc. (now Honeywell International), progressing through a series of financial management positions and served as its Corporate Treasurer. He started his career at Franklin Mint Corp. He served as Vice Chairman of Life and Analytical Sciences unit since January 2006. He serves as a Director of Fairchild Semiconductor Corp. He has been a Director of Analytical and Life Science Systems Association since January 1, 2006, NuVasive, Inc. since February 2016. He has been an Independent Director of Xylem Inc. since December 13, 2012. He has been Director of New York Life Insurance Company since January 1, 2019. He serves on the Board of March of Dimes Foundation. He served as an Independent Director of CareFusion Corporation from June 9, 2009 to March 17, 2015. He served as a Director of Millennium Pharmaceuticals, Inc. since June 15, 2005 and Fairchild Semiconductor International Inc., from March 31, 2004 to May 6, 2009. Mr. Friel holds a Bachelor of Arts degree in Economics from Lafayette College and a Master of Science degree in Taxation from Farleigh Dickinson University.

CEO Compensation
  • Rob's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Rob's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the PerkinElmer management team in years:

3.1
Average Tenure
49.5
Average Age
  • The tenure for the PerkinElmer management team is about average.
Management Team

Rob Friel

TITLE
Chairman & CEO
COMPENSATION
$14M
AGE
62
TENURE
11.3 yrs

Prahlad Singh

TITLE
President & COO
COMPENSATION
$2M
AGE
53
TENURE
0.3 yrs

Jamey Mock

TITLE
Senior VP & CFO
COMPENSATION
$4M
AGE
41
TENURE
1 yrs

Joel Goldberg

TITLE
Senior VP of Administration
COMPENSATION
$3M
AGE
49
TENURE
10.8 yrs

Andrew Okun

TITLE
VP & Chief Accounting Officer
AGE
48
TENURE
8.1 yrs

Bryan Kipp

TITLE
Vice President of Investor Relations

Deborah Butters

TITLE
Senior VP & Chief Human Resources Officer
AGE
48
TENURE
2.8 yrs

Daniel Tereau

TITLE
Senior Vice President of Strategy & Business Development
AGE
50
TENURE
3.3 yrs

Tajinder Vohra

TITLE
Senior Vice President of Global Operations
AGE
52
TENURE
1.3 yrs

Dave Francisco

TITLE
CFO of Human Health & Corporate Treasurer
Board of Directors Tenure

Average tenure and age of the PerkinElmer board of directors in years:

4.3
Average Tenure
61
Average Age
  • The tenure for the PerkinElmer board of directors is about average.
Board of Directors

Rob Friel

TITLE
Chairman & CEO
COMPENSATION
$14M
AGE
62
TENURE
10.1 yrs

Alexis Michas

TITLE
Lead Director
COMPENSATION
$337K
AGE
60

Pat Sullivan

TITLE
Independent Director
COMPENSATION
$269K
AGE
66
TENURE
11.3 yrs

Peter Barrett

TITLE
Independent Director
COMPENSATION
$276K
AGE
65
TENURE
7.3 yrs

Sam Chapin

TITLE
Independent Director
COMPENSATION
$290K
AGE
60
TENURE
2.6 yrs

Frank Witney

TITLE
Independent Director
COMPENSATION
$265K
AGE
64
TENURE
2.8 yrs

Sylvie Grégoire

TITLE
Independent Director
COMPENSATION
$265K
AGE
57
TENURE
4.3 yrs

Pascale Witz

TITLE
Director
COMPENSATION
$265K
AGE
51
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
07. Feb 19 Sell Nicholas Lopardo Individual 05. Feb 19 05. Feb 19 -1,600 €81.24 €-129,991
04. Dec 18 Sell Alexis Michas Individual 03. Dec 18 03. Dec 18 -5,000 €80.10 €-400,498
03. Dec 18 Sell Nicholas Lopardo Individual 30. Nov 18 30. Nov 18 -2,000 €76.91 €-153,818
14. Nov 18 Sell Patrick Sullivan Individual 13. Nov 18 13. Nov 18 -10,000 €72.34 €-723,412
07. Nov 18 Sell Pascale Witz Individual 06. Nov 18 06. Nov 18 -2,206 €73.26 €-161,619
06. Nov 18 Sell Nicholas Lopardo Individual 05. Nov 18 05. Nov 18 -2,000 €72.02 €-144,042
04. Sep 18 Sell Nicholas Lopardo Individual 31. Aug 18 31. Aug 18 -2,700 €79.50 €-214,648
29. Aug 18 Sell Nicholas Lopardo Individual 28. Aug 18 28. Aug 18 -3,500 €76.30 €-267,060
07. Aug 18 Sell Nicholas Lopardo Individual 06. Aug 18 06. Aug 18 -3,505 €73.98 €-259,314
X
Management checks
We assess PerkinElmer's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. PerkinElmer has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PKN News

Simply Wall St News

PKN Company Info

Description

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Details
Name: PerkinElmer, Inc.
PKN
Exchange: DB
Founded: 1937
$8,546,313,211
110,918,491
Website: http://www.perkinelmer.com
Address: PerkinElmer, Inc.
940 Winter Street,
Waltham,
Massachusetts, 02451,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NYSE PKI Common Stock New York Stock Exchange US USD 02. Jan 1968
DB PKN Common Stock Deutsche Boerse AG DE EUR 02. Jan 1968
LSE 0KHE Common Stock London Stock Exchange GB USD 02. Jan 1968
Number of employees
Current staff
Staff numbers
12,500
PerkinElmer employees.
Industry
Life Sciences Tools and Services
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/26 21:08
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/04/29
Last earnings filing: 2019/05/07
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.